Logo image of QURE

UNIQURE NV (QURE) Stock Fundamental Analysis

NASDAQ:QURE - Nasdaq - NL0010696654 - Common Stock - Currency: USD

15.34  -0.65 (-4.07%)

After market: 15.76 +0.42 (+2.74%)

Fundamental Rating

2

Taking everything into account, QURE scores 2 out of 10 in our fundamental rating. QURE was compared to 559 industry peers in the Biotechnology industry. Both the profitability and financial health of QURE have multiple concerns. QURE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

QURE had negative earnings in the past year.
In the past year QURE has reported a negative cash flow from operations.
QURE had negative earnings in 4 of the past 5 years.
In the past 5 years QURE reported 4 times negative operating cash flow.
QURE Yearly Net Income VS EBIT VS OCF VS FCFQURE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

1.2 Ratios

With a decent Return On Assets value of -35.94%, QURE is doing good in the industry, outperforming 60.29% of the companies in the same industry.
Looking at the Return On Equity, with a value of -645.89%, QURE is doing worse than 80.50% of the companies in the same industry.
Industry RankSector Rank
ROA -35.94%
ROE -645.89%
ROIC N/A
ROA(3y)-32.71%
ROA(5y)-18.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
QURE Yearly ROA, ROE, ROICQURE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

QURE has a better Gross Margin (53.97%) than 78.00% of its industry peers.
In the last couple of years the Gross Margin of QURE has declined.
The Profit Margin and Operating Margin are not available for QURE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.17%
GM growth 5YN/A
QURE Yearly Profit, Operating, Gross MarginsQURE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

QURE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, QURE has more shares outstanding
QURE has more shares outstanding than it did 5 years ago.
The debt/assets ratio for QURE is higher compared to a year ago.
QURE Yearly Shares OutstandingQURE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
QURE Yearly Total Debt VS Total AssetsQURE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

QURE has an Altman-Z score of -1.92. This is a bad value and indicates that QURE is not financially healthy and even has some risk of bankruptcy.
QURE has a Altman-Z score (-1.92) which is comparable to the rest of the industry.
QURE has a Debt/Equity ratio of 14.79. This is a high value indicating a heavy dependency on external financing.
QURE has a worse Debt to Equity ratio (14.79) than 84.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 14.79
Debt/FCF N/A
Altman-Z -1.92
ROIC/WACCN/A
WACC7.02%
QURE Yearly LT Debt VS Equity VS FCFQURE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

QURE has a Current Ratio of 11.99. This indicates that QURE is financially healthy and has no problem in meeting its short term obligations.
QURE has a better Current ratio (11.99) than 83.01% of its industry peers.
A Quick Ratio of 11.99 indicates that QURE has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 11.99, QURE belongs to the best of the industry, outperforming 83.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.99
Quick Ratio 11.99
QURE Yearly Current Assets VS Current LiabilitesQURE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.00% over the past year.
Looking at the last year, QURE shows a small growth in Revenue. The Revenue has grown by 6.43% in the last year.
Measured over the past years, QURE shows a very strong growth in Revenue. The Revenue has been growing by 30.01% on average per year.
EPS 1Y (TTM)29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.71%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y-62.73%
Revenue growth 5Y30.01%
Sales Q2Q%-81.53%

3.2 Future

Based on estimates for the next years, QURE will show a very negative growth in Earnings Per Share. The EPS will decrease by -52.47% on average per year.
Based on estimates for the next years, QURE will show a very strong growth in Revenue. The Revenue will grow by 78.82% on average per year.
EPS Next Y25.99%
EPS Next 2Y19.16%
EPS Next 3Y15.1%
EPS Next 5Y-52.47%
Revenue Next Year-14.28%
Revenue Next 2Y72.77%
Revenue Next 3Y49.93%
Revenue Next 5Y78.82%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
QURE Yearly Revenue VS EstimatesQURE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
QURE Yearly EPS VS EstimatesQURE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

QURE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QURE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QURE Price Earnings VS Forward Price EarningsQURE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QURE Per share dataQURE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as QURE's earnings are expected to grow with 15.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.16%
EPS Next 3Y15.1%

More info and screens

0

5. Dividend

5.1 Amount

QURE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNIQURE NV

NASDAQ:QURE (6/13/2025, 8:00:01 PM)

After market: 15.76 +0.42 (+2.74%)

15.34

-0.65 (-4.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)07-31 2025-07-31/bmo
Inst Owners91.37%
Inst Owner Change17.28%
Ins Owners1.66%
Ins Owner Change3.36%
Market Cap839.87M
Analysts84
Price Target37 (141.2%)
Short Float %14.16%
Short Ratio3.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-59.79%
Min EPS beat(2)-139.62%
Max EPS beat(2)20.04%
EPS beat(4)3
Avg EPS beat(4)-24.71%
Min EPS beat(4)-139.62%
Max EPS beat(4)20.04%
EPS beat(8)3
Avg EPS beat(8)-49%
EPS beat(12)6
Avg EPS beat(12)-26.16%
EPS beat(16)9
Avg EPS beat(16)0.65%
Revenue beat(2)0
Avg Revenue beat(2)-73.43%
Min Revenue beat(2)-75.51%
Max Revenue beat(2)-71.35%
Revenue beat(4)1
Avg Revenue beat(4)-38.87%
Min Revenue beat(4)-75.51%
Max Revenue beat(4)58.38%
Revenue beat(8)3
Avg Revenue beat(8)-37.37%
Revenue beat(12)4
Avg Revenue beat(12)-14.89%
Revenue beat(16)6
Avg Revenue beat(16)15.2%
PT rev (1m)1.01%
PT rev (3m)-0.89%
EPS NQ rev (1m)0.67%
EPS NQ rev (3m)10.74%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.41%
Revenue NQ rev (1m)-7.67%
Revenue NQ rev (3m)-7.78%
Revenue NY rev (1m)-20.79%
Revenue NY rev (3m)-4.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 41.58
P/FCF N/A
P/OCF N/A
P/B 24.93
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.41
EYN/A
EPS(NY)-2.87
Fwd EYN/A
FCF(TTM)-3.06
FCFYN/A
OCF(TTM)-3.04
OCFYN/A
SpS0.37
BVpS0.62
TBVpS-1.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.94%
ROE -645.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.97%
FCFM N/A
ROA(3y)-32.71%
ROA(5y)-18.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.17%
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 14.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.91%
Cap/Sales 5.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.99
Quick Ratio 11.99
Altman-Z -1.92
F-Score5
WACC7.02%
ROIC/WACCN/A
Cap/Depr(3y)98.33%
Cap/Depr(5y)124.6%
Cap/Sales(3y)24.73%
Cap/Sales(5y)20.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.71%
EPS Next Y25.99%
EPS Next 2Y19.16%
EPS Next 3Y15.1%
EPS Next 5Y-52.47%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y-62.73%
Revenue growth 5Y30.01%
Sales Q2Q%-81.53%
Revenue Next Year-14.28%
Revenue Next 2Y72.77%
Revenue Next 3Y49.93%
Revenue Next 5Y78.82%
EBIT growth 1Y36.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.34%
EBIT Next 3Y15.72%
EBIT Next 5Y50.02%
FCF growth 1Y21.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.91%
OCF growth 3YN/A
OCF growth 5YN/A